<DOC>
	<DOCNO>NCT01227187</DOCNO>
	<brief_summary>The purpose study assess safety Xigris ( Drotrecogin alfa ) anticoagulant different dose level dialysis treatment patient End Stage Renal Disease ( ESRD ) .</brief_summary>
	<brief_title>Safety Dose Finding Study Xigris Hemodialysis Patients</brief_title>
	<detailed_description>In United States , 300,000 patient ESRD require hemodialysis . Clinical hemodialysis take place three time week dependent adequate anticoagulation throughout three four hour procedure . Infection one common cause death patient ESRD treat hemodialysis ( 25 % ) . Xigris ( drotrecogin alfa activate ) recombinant form human activate protein C successfully use treatment adult patient severe sepsis . In addition fibrinolytic property , drotrecogin alpha anti-inflammatory effect , anti-coagulant effect . However , safety efficacy data effect Xigris ESRD patient anticoagulant .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Drotrecogin alfa activate</mesh_term>
	<mesh_term>Protein C</mesh_term>
	<criteria>1 . &gt; 18 2 . Usually use heparin HD 1 . Plt &lt; 100 2 . Pregnancy 3 . H/o bleed diathesis 4 . H/o CVA 5 . Pt Ticlid/plavix/warfarin 6 . SBP &gt; 200 7 . BASELINE PTT &gt; 50 8 . INR &gt; 1.6</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Hemodialysis</keyword>
	<keyword>Anticoagulation</keyword>
	<keyword>Xigris</keyword>
	<keyword>PTT</keyword>
</DOC>